Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214894 | 1.00 | ENPP2 (0.57) | ENPP2GRIN1GRIN2BDCTPP1MCHR1 | |
| SCHEMBL6876895 | 0.91 | MEN1 (0.57) | GRIN1GRIN2BDCTPP1MAPTAVPR1A | |
| SCHEMBL6876887 | 0.91 | MEN1 (0.57) | GRIN1GRIN2BDCTPP1MAPTAVPR1A | |
| SCHEMBL6865640 | 0.83 | ENPP2 (0.67) | ENPP2GRIN1GRIN2BDCTPP1MCHR1 | |
| SCHEMBL6865646 | 0.83 | ENPP2 (0.67) | ENPP2GRIN1GRIN2BDCTPP1MCHR1 | |
| SCHEMBL7038765 | 0.82 | MAPT (0.54) | GRIN1GRIN2BDCTPP1MAPTAVPR1A | |
| SCHEMBL7039412 | 0.81 | ALOX5 (0.49) | GRIN1GRIN2BDCTPP1MAPTAVPR1A | |
| SCHEMBL6876477 | 0.79 | ALOX5 (0.47) | GRIN1GRIN2BDCTPP1MAPTAVPR1A | |
| SCHEMBL6073902 | 0.78 | MAPT (0.55) | MAPTRAB9AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6073906 | 0.78 | MAPT (0.55) | MAPTRAB9AALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821991-B2 | FOR THERAPY OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA (ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE), ATHEROSCLEROSIS, GASTROINTESTINAL DISORDERS, NEUROGENETIC INFLAMMATION, FREQUENT URINATION | WYETH | 2004-11-23 | — | — | US | disclosed |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2003-09-18 | — | — | US | disclosed |
| US-6583140-B2 | Useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders | WYETH | 2003-06-24 | — | — | US | disclosed |
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | WYETH | 2002-11-14 | — | — | US | disclosed |
| US-6410734-B1 | INSULIN RESISTANCE; HYPOGLYCEMIC AGENTS; ANTICHOLESTEROL AGENTS; GASTROINTESTINAL DISORDERS | WYETH | 2002-06-25 | — | — | US | disclosed |
| WO-2002006281-A1 | 2-SUBSTITUTED THIAZOLIDINONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169325-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ENPP2 2468/4885GRIN1 1147/4885GRIN2B 742/4885 |
| US-20030176412-A1 | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ENPP2 2468/4885GRIN1 1147/4885GRIN2B 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.